AstraZeneca executives at earnings conference, February 2020 (Natalie Grover for Endpoints News)

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

LON­DON — With near­ly a fifth of to­tal sales com­ing from Chi­na, As­traZeneca counts the coro­n­avirus-hit na­tion as one of its biggest growth dri­vers. The im­pact of the dead­ly epi­dem­ic has un­sur­pris­ing­ly weighed on the British drug­mak­er’s fourth-quar­ter re­sults.

On Fri­day, As­traZeneca post­ed fourth-quar­ter sales of $6.25 bil­lion, just shy of Wall Street es­ti­mates. Near­ly $1.2 bil­lion of that prod­uct rev­enue came from Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.